SLC12A5 and spinal cord injury: Since KCC2 agonists have been proposed for the treatment of spinal cord injuries (Hegarty and Stanicka, 2022), the transient downregulation of KCC2 in a denervated brain area suggests that treatment with KCC2 agonists could not only affect reorganization processes at injury sites but also brain rewiring in connected brain regions.